About Regentys
Regentys is a Healthcare company based in Miami (United States) founded in 2009 by Marc Ramer, Rick Bulman, Gerard S Coombs, and Christine V Sapan, and was acquired by Generex Biotechnology in January 2019. Regenerative medicines for gastrointestinal disorders are developed. Regentys has raised $4.35 million across 6 funding rounds from investors including Generex Biotechnology and 43North. Its chief executive, as recorded, is Rick Bulman. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its competitors include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2009 and based in Miami, United States, focus is placed on the biotechnology sector through the development of regenerative therapies for gastrointestinal conditions. Operations center on the creation of Extracellular Matrix Hydrogel (ECMH), a porcine-derived product administered rectally to serve as a barrier and scaffold for mucosal repair in ulcerative colitis treatment. Leadership includes multiple co-founders guiding product advancement.
- Headquarters Miami, United States
- Founders Marc Ramer, Rick Bulman, Gerard S Coombs, Christine V Sapan
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website regentys.com
- Social LinkedIn X Facebook YouTube
- Acquired by Generex Biotechnology (Jan 2019)
- Total Equity Funding$4.35M (USD)
in 6 rounds
- Latest Funding Round$1.45M (USD), Series A
Nov 2016
- InvestorsGenerex Biotechnology
& 1 more
- Acquired byGenerex Biotechnology
(Jan 2019)
Apps and channels of Regentys
its YouTube channel Regentys has 9 subscribers and 6 videos.
Videos from Regentys
The most watched videos on Regentys's YouTube channel, Regentys (9 subscribers). Click a video to play it here.
More on Regentys.
Funding Insights of Regentys
Regentys has successfully raised a total of $4.35M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $1.45 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.35M
- Total Rounds 6
- Last Round Series A — $1.45M
- First Round $250,000
(Jul 2009)
- Investors Count 1
All 6 funding rounds of Regentys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | $1.45M | Series A | – | – | – |
| Jun 2016 | $1.45M | Seed | – | – | – |
| May 2016 | $1.2M | Series A | – | – | – |
| Nov 2014 | $250,000 | Grant | – | – | |
| Sep 2014 | $200,000 | Debt – Conventional | – | – | – |
| Jul 2009 | $250,000 | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Regentys
Regentys has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Generex Biotechnology and 43North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seed-stage investments are targeted by 43North in startups. | 43north.org | Buffalo, United States | ||
Technologies for large molecule drug delivery are developed. | 1983 | generex.com | Miramar, United States |
Investor details for Regentys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Regentys
4 people are tracked at Regentys (4 in leadership).
| Name | Role | Group |
|---|---|---|
Marc Ramer | Co-Founder | Leadership |
Rick Bulman | Co-Founder & CEO | Leadership |
Gerard S Coombs | Co-Founder | Leadership |
Christine V Sapan | Co-Founder & CEO | Leadership |
Complete people profiles for Regentys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Regentys
4 dated milestones of Regentys across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Regentys is founded.
- Funding First funding round of $250K.
- Funding Latest funding round, Series A, of $1.5M.
- Exit Acquired by Generex Biotechnology.
Competitors of Regentys
Regentys has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, Escient Pharmaceuticals and Nimbus Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| escientpharma.com | 2017 | San Diego, United States | $237.5M | 44 | Small molecule therapeutics for inflammatory diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. |
Detailed competitors of Regentys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Regentys
The website of Regentys (regentys.com) receives about 1.4K visits a month.
- Monthly visits1.4K
▼ 35.1% vs previous month
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Regentys (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Regentys
Complete news archive for Regentys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Regentys
Regentys was founded in 2009.
Regentys is headquartered in Miami, United States. It is registered at Miami, Florida, United States.
Rick Bulman is the CEO of Regentys, as recorded in our data. They have also founded this company.
Regentys is a funded company, having raised a total of $4.35M across 6 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Jul 2009.
Founded in 2009 and based in Miami, United States, focus is placed on the biotechnology sector through the development of regenerative therapies for gastrointestinal conditions. Operations center on the creation of Extracellular Matrix Hydrogel (ECMH), a porcine-derived product administered rectally to serve as a barrier and scaffold for mucosal repair in ulcerative colitis treatment. Leadership includes multiple co-founders guiding product advancement.
Regentys's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Aclaris Therapeutics.
Regentys has 2 investors. Key investors include Generex Biotechnology, and 43North.
Yes. Regentys was acquired by Generex Biotechnology in January 2019.